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Background: Superficial venous surgery (SVS) results in a significant improvement in generic health-related quality of life
(HRQL). However, it is unclear how this improvement compares with that observed after other commonly performed
general and vascular operations. The aim of this study was to compare the changes in generic HRQL observed before and
after SVS for CEAP clinical grade 2 to 4 venous disease with those observed before and after elective laparoscopic
cholecystectomy (ELC) for biliary colic.
Methods: The Short Form 12 questionnaire was mailed to patients before and 3, 6, and 12 months after SVS (n  143)
and ELC (n  60). The responses were used to calculate physical (PCS) and mental (MCS) component summary scores
at each time point. A higher score indicates a better HRQL.
Results: Before surgery and 3 and 12 months after surgery, patients in the ELC group had a significantly lower PCS than
those in the SVS group (40.2 vs 49.5, 48.9 vs 53.1, and 45.4 vs 53.8; P < .001, P  .033, and P < .001, respectively;
Mann-WhitneyU test). However, the change in PCS observed over the first 12 postoperative months was not significantly
different between the SVS and ELC groups. Patients in the ELC group had a significantly lower MCS than those in the
SVS group before surgery (45.9 vs 50.8; P .002; Mann-WhitneyU test), but not after surgery. There was no difference
between the two groups in terms of postoperative change in MCS.
Conclusions: SVS is associated with a statistically significant and clinically meaningful improvement in generic HRQL that
is similar to that observed after ELC. These novel data lend further support to the clinical benefit of SVS and will help
health care purchasers make decisions regarding the prioritization of vascular and general surgical services. ( J Vasc Surg
2006;44:606-10.)Lower limb venous disease affects up to one third of the
adult population in developed countries1 and leads to
symptoms, complications such as chronic venous ulcer-
ation, and a reduction in health-related quality of life
(HRQL).2,3 It is widely accepted that superficial venous
surgery (SVS) relieves symptoms, improves HRQL,2,4,5
and prevents chronic venous ulceration recurrence.6 De-
spite this impressive evidence base, the funding of operative
procedures for non–life-threatening chronic conditions
such as chronic venous disease is given low priority world-
wide, for example, in the United Kingdom, where SVS has
frequently been subject to rationing in the publicly funded
National Health Service.7,8 The prime motivation behind
the imposition of limits to health resource allocation is a
desire to limit spending.9,10 Some might argue that given
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606ever-increasing patient expectations, technological ad-
vances, and costs, rationing is inevitable within any health
care system. However, as with any tough clinical decision,
the decision to ration services should be evidence based.
Traditional surgical outcomes, such as morbidity and
mortality, are crude, often fail to recognize the patient’s
underlying concerns and satisfaction with treatment, and
are clearly insufficient and inappropriate in the context of
SVS. As a result, patient-reported outcomes using vali-
dated HRQL instruments are increasingly used to assess
treatment effects.11 Generic HRQL instruments also
allow clinically unrelated treatments to be compared; for
example, how does hip replacement compare (in terms of
the patients’ opinions of improved physical and psycho-
logical function) with coronary artery bypass grafting?
Such comparative data can then be used to optimize the
clinical effectiveness and cost-effectiveness of different
treatments and to facilitate difficult decisions regarding
the prioritization of services. To our knowledge, the
patient-reported benefits of SVS have not previously
been compared with those observed after other com-
monly performed general and vascular operations. Thus,
the aim of this study was to compare the changes in
generic HRQL observed before and after SVS for CEAP
2 to 4 venous disease12 with those observed before and
after elective laparoscopic cholecystectomy (ELC) for
biliary colic.
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After local ethical committee approval and written in-
formed consent, patients were recruited from waiting lists
for either SVS or ELC over a year.
SVS group. In the SVS group, patients were eligible
for the study if, on physical examination, they had symp-
tomatic CEAP clinical grade 2 to 4 venous disease12 and,
on duplex ultrasonography, significant (0.5 seconds)
truncal venous reflux. No procedure was performed for
cosmesis alone. All surgical procedures were performed
with the patient under general anesthesia and were either
primary or redo great saphenous vein (GSV; ligation of the
saphenofemoral junction; routine stripping of GSV to
knee) or small saphenous vein (SSV; ligation of the saphe-
nopopliteal junction; selected stripping of the SSV) opera-
tions, with multiple stab avulsions. Patients undergoing
sclerotherapy and subfascial endoscopic perforator surgery
were excluded.
ELC group. In the ELC group, patients were eligible
if, in the opinion of the attending laparoscopic surgeon,
they had biliary colic due to cholelithiasis and required ELC
for relief of symptoms. All procedures were performed with
patients under general anesthesia. Patients with complica-
tions of gallstones (pancreatitis, cholecystitis, or cholangi-
tis), those who underwent conversion to open surgery, or
those who required exploration of the common bile duct
were excluded.
Patients in both groups were mailed a Short Form 12
(SF-12) questionnaire 2 to 4 weeks before surgery and 3, 6,
and 12 months after surgery. Mailing was used to minimize
the bias observed with face-to-face administration of
HRQL instruments by health care professionals.13 Nonre-
sponders were sent two additional reminders. The SF-1214
is a fully validated and widely used measure of generic
HRQL derived from the Short Form 36 (SF-36). Re-
sponses to the 12 questions were used to calculate physical
(PCS) and mental (MCS) component summary scores.14
All patients who returned their preoperative questionnaires
were included in the analysis.
The statistical adviser was Tim Marshall, MSc, of the
Department of Public Health and Epidemiology at the
University of Birmingham. Statistical analysis was per-
formed with SPSS 11.0 (SPSS Inc, Chicago, Ill). For non-
normally distributed data, nonparametric tests were used,
with the Mann-WhitneyU test for continuous data and the
2 or Fisher exact test for categorical data when comparing
the two groups of patients.
Because this study was not matched, to look at the
effects of age, sex, and operation type on the observed
change in PCS after surgery, regression analysis was per-
formed with change in PCS as the dependent variable, age
as a continuous variable, and sex and operation type as
indicator-independent variables. A level of significance of P
 .05 was taken as proof of the validity of each model.
On the basis of work conducted by the Medical Out-
comes Group,14,15 it was estimated by using a two-tailed
test with a false rejection rate of 5% and statistical power of80% that a sample size of 46 respondents would be required
to detect a difference of 5 points between groups in terms
of the change inHRQL observed before and after interven-
tion.
RESULTS
Patients. The response rate was 83% in the SVS group
and 60% in the ELC group. Thus, the patients available for
the study were as follows: in the SVS group, there were 143
patients (35% men) of a median age of 43 years (interquar-
tile range, 37-56 years). In the ELC group, there were 60
patients (17% men) of a median age of 56 years (interquar-
tile range, 48-65 years).
The ELC group patients were significantly older than
those in the SVS group (P  .001; Mann-Whitney U test)
and less likely to be male (P  .015; Yates’ corrected 2
test). In the SVS group, 121 (85%) had CEAP clinical grade
C2 to C3 disease, and 22 (15%) had C4 disease. Primary
surgery was performed in most (84%), and 27% had bilat-
eral procedures. The anatomic distribution of the proce-
dures was GSV, 126 (88%); GSV only, 119 (84%); SSV, 24
(16%); SSV only, 17 (11%); and combined GSV and SSV, 7
(5%). In addition, all patients underwent stab avulsions.
At each postoperative time point, some patients did not
return a completed questionnaire. This resulted in a re-
sponse rate at 3, 6, and 12 months of 75%, 76%, and 68%
for SVS and 72%, 68%, and 75% for ELC. The nonre-
sponders were more likely to be younger (median age, 42.4
vs 53.1 years; P  .002; Mann-Whitney U test), but the
postoperative response rate was unaffected by sex and op-
eration type.
Physical component summary. In the ELC group,
there was a significant improvement in PCS over the first
three postoperative months, from a median of 40.2 to 48.9
(P  .001; Wilcoxon signed ranks test), and this was
sustained at 6 and 12 months (preoperative vs 6 months,
40.2 vs 49.2 [P  .001]; preoperative vs 12 months, 40.2
vs 45.4 [P  .006]; Wilcoxon signed ranks test). This
improvement was all achieved in the first three postopera-
tive months, with no significant further change being ob-
served thereafter (Fig 1). Similarly, in the SVS group, PCS
improved significantly over the first three postoperative
months, from 49.5 to 53.1 (P  .001; Wilcoxon signed
ranks test), and this improvement was sustained at 6 and 12
months (preoperative vs 6 months, 49.5 vs 52.1 [P 
.007]; preoperative vs 12 months, 49.5 vs 53.8 [P .001];
Wilcoxon signed ranks test), with no significant change
between each of the postoperative time points (Fig 1).
Patients in the ELC group had a significantly lower
(worse) PCS than the SVS group before surgery and at 3
and 12 months after surgery, but not at 6 months (Fig 1).
The magnitude of the postoperative improvement in PCS
(change in PCS) was significantly higher in the ELC group
at 6 months, but there was no significant difference be-
tween the SVS and ELC groups at 3 or 12 months (Fig 2).
Mental component summary. In the ELC group,
there was no significant improvement in MCS over the first
three postoperative months. Although there was a significant
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months (preoperative vs 3 months, 45.9 vs 53.0 [P .387];
preoperative vs 6 months, 45.9 vs 52.1 [P .029]; preoper-
ative vs 12months, 45.9 vs 49.5 [P .320];Wilcoxon signed
ranks test; Fig 3). In the SVS group, there was no significant
Fig 1. Physical component summary (PCS) scores before and at
3, 6, and 12 months after surgery. The reference line at 50
indicates the average score in the general population. Comparison
of superficial venous surgery (SVS) vs elective laparoscopic chole-
cystectomy (ELC): *Before surgery: median, 49.5 vs 40.2; P 
.001; Mann-WhitneyU test. **Three months (3m): 53.1 vs 48.9;
P  .033. ***Six months (6m): 52.1 vs 49.2; P  0.108.
****Twelve months (12m): 53.8 vs 45.4; P  .001.
Fig 2. Change in physical component summary (PCS) scores
after surgery. Comparison of superficial venous surgery (SVS) vs
elective laparoscopic cholecystectomy (ELC): *Before surgery to 3
months (3m): median change, 2.3 vs 5.7; P  .151; Mann-
WhitneyU test. **Before surgery to 6 months (6m): 2.1 vs 3.0; P
 .048. ***Before surgery to 12 months (12m): 1.7 vs 2.4; P 
.535.postoperative improvement in MCS (Fig 3).The ELC group had a significantly lowerMCS than the
SVS group before surgery but not at 3, 6, or 12 months
after surgery (Fig 3). The change in MCS over the first 12
months was not significantly different between the two
groups.
Effect of age. As has been found in other studies,
considering the study group as a whole, age correlated
negatively with PCS at all four time points (Spearman r 
0.175, 0.269, 0.245, and 0.355; P  .013, .001,
.003, and .001). However, there was no relationship
between age and the change in PCS after surgery.
To investigate the effects of age, sex, and operation
type on the change in PCS after intervention, regression
analysis was performed. First, tests of normality (Kol-
mogorov-Smirnov) were used to confirm that the ob-
served differences (changes) in PCS were normally dis-
tributed in both groups at 3 and 6 months (3 months:
ELC, P  .200; SVS, P  .104; 6 months: ELC, P 
.079; SVS, P  .167) and for ELC only at 12 months (P
 .094). However, although the data in the SVS group
for 12 months were not normally distributed, it is worth
noting that the t test is robust to marked departures from
normality.16
Next, a linear regression model was used with change
in PCS as the dependent variable, age as a measured
independent variable, and sex and operation as indicator-
independent variables. Looking at the change in PCS at
each postoperative time point, neither the patient’s age
or sex nor the type of operation significantly affected the
model, thus indicating that the observed change in PCS
Fig 3. Mental component summary (MCS) scores before and at
3, 6, and 12 months after surgery. Comparison of superficial
venous surgery (SVS) vs elective laparoscopic cholecystectomy
(ELC): *Before surgery: median, 50.8 vs 45.9; P  .002; Mann-
Whitney U test. **Three months (3m): 52.6 vs 53.0; P  .675.
***Six months (6m): 54.1 vs 52.1; P .224. ****Twelve months
(12m): 53.3 vs 49.5; P  .044.is independent of age, sex, and, again, type of operation.
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The main novel finding in this study is that the magni-
tude of the improvement in physical generic HRQL, as
determined by the SF-12 PCS, observed after SVS for
uncomplicated (CEAP clinical grade C2 to C4) lower limb
venous disease is similar to that observed after ELC for
uncomplicated cholelithiasis (biliary colic). This was de-
spite the fact that the preoperative and postoperative PCS
scores were significantly lower in the ELC group compared
with the SVS group and despite the differences in age and
sex between the two groups.
The SF-12 is a respected and widely used generic
measure of HRQL derived from the SF-36.14,17-19 These
generic measures assess the dimensions of life that are
common to all patients, whereas disease-specific measures
assess the effect of a disease on a patient in finer detail. It is
accepted that both generic and disease-specific measures of
HRQL are important in determining outcome after inter-
ventions.11 However, although generic instruments may be
less sensitive to small, but nevertheless important, treat-
ment effects, they do allow clinically dissimilar conditions
to be compared—a task disease-specific instruments are
unable to perform because of the specificity of the mea-
sures. To our knowledge, this is the first study to compare
patient-reported outcomes after SVS with those observed
after other commonly performed general and vascular op-
erations.
Although some form of rationing is probably inevitable
within any health care system, whether that be in the
United Kingdom,7,8 United States,10 or worldwide, such
decisions should be evidence based in the light of outcomes
data. Unfortunately, despite a strong evidence base sup-
porting the clinical effectiveness of SVS, such surgery has
frequently been the target of arbitrary rationing within the
UK National Health Service.8 By contrast, there are no
known instances of patients with symptomatic cholelithiasis
being denied ELC on grounds of cost or clinical ineffec-
tiveness. As such, we hope that the present data will allow
health care purchasers and providers worldwide to make
evidence-based decisions regarding the services they wish
to buy and supply.
This study has several limitations. Face-to-face admin-
istration of HRQL questionnaires has been shown to im-
prove individual questionnaire item and overall response
rates.13 However, it is also generally accepted that the data
may be less honest and reliable, and, for that reason, as we
have done in our previously published studies,2,4 we chose
to administer the questionnaires by mail.13 The response
rate in the ELC group was lower than that of the SVS
group, although it was comparable to other questionnaire-
based studies. This may be because the SVS patients were
also taking part in other outcome studies (Sam RC et al.
Patient reported outcomes after superficial venous surgery–
relationships with change in venous haemodynamics. Pre-
sented at the American Venous Forum, Miami, Fla, 2006)
requiring attendance for hospital-based postoperative in-
vestigations. Power calculations based on studies in USpopulations affected by other common diseases suggested
that a minimum of 46 samples would be required at each
time point to show a significant difference between the
improvement observed after SVS and that observed after
ELC.15 In the ELC group, the numbers were only 43, 41,
and 45 at 3, 6, and 12 months, respectively. Thus, it is
possible that the failure to find a difference between these
groups represents a type II error and that such a difference
may be found in a larger study. Increasing the duration of
the study might have allowed more patients with biliary
colic to be recruited, which would have solved this di-
lemma.
There were significant differences in age and sex be-
tween the two patient groups included in this study. Using
an age- and sex-matched comparison would have removed
this problem. However, in previous questionnaire-based
studies, as in this study, we observed that some patients,
after being enrolled, failed to return forms, or, if returned,
the forms were incompletely filled in, a problem other
researchers have also found.13 Thus, given this expected
dropoff in responses, we believed that this would have led
to an unacceptably low proportion of patients able to be
included in the final analysis, therefore reducing the appli-
cability of our study. On the basis of the experience and
results of this novel study, future larger-scale studies would
be able to use age and sex matching to reduce the effect of
these confounding factors.
The question as to whether statistically significant nu-
merical differences generated for HRQL instruments
equate with clinical significance may never be answered.
Although various statistical methods have been used to
provide numerical thresholds above which a patient is be-
lieved to perceive a real treatment benefit, resulting in the
treatment’s being recommended, it must be remembered
that suchmethods are actually based on opinion rather than
evidence. In addition, many studies have found very small
differences in HRQL scores that could be interpreted as
clinically relevant.20
In conclusion, SVS is associated with a statistically
significant and clinically meaningful improvement in ge-
neric HRQL that is similar to that observed after ELC.
These novel data lend further support to the clinical benefit
of SVS and will help health care purchasers make decisions
regarding the prioritization of vascular and general surgical
services.
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